Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia

Rimonabant, a selective cannabinoid-1 (CB1) receptor antagonist, has been shown to reduce weight and enhance improvements in cardiometabolic risk parameters in Western populations. This study assessed these effects of rimonabant in Asian population. A total of 643 patients (BMI 25 kg/m(2) or greater...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Changyu, Yoo, Hyung Joon, Ho, Low-Tone
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021887/
https://www.ncbi.nlm.nih.gov/pubmed/21253513
http://dx.doi.org/10.1155/2011/957268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021887/
https://www.ncbi.nlm.nih.gov/pubmed/21253513
http://dx.doi.org/10.1155/2011/957268

Ejemplares similares